https://www.d3bio.com https://www.d3bio.com/press-releases/d3-bio-received-ind-clearance-from-fda-to-initiate-phase-i-clinical-trial-in-us-for-d3s-001 https://www.d3bio.com/press-releases/d3-bio-announces-data-presentation-at-the-34th-eortc-nci-aacr-symposium https://www.d3bio.com/press-releases/d3-bio-announces-data-presentations-at-the-society-for-immunotherapy-of-cancer-2022 https://www.d3bio.com/press-releases/d3-bios-d3s-001-receives-u-s-fda-fast-track-designation-for-the-treatment-of-colorectal-cancer-with-kras-g12c-mutation https://www.d3bio.com/d3-bio-policy-on-expanded-access-program https://www.d3bio.com/press-releases/d3-bio-announces-receiving-an-orphan-drug-designation-and-two-ind-clearances-from-fda-for-its-compounds-and-presentation-of-pipeline-data-at-upcoming-aacr-2023 https://www.d3bio.com/press-releases/d3-bio-appoints-dr-antoine-yver-as-independent-board-member https://www.d3bio.com/press-releases/d3-bio-announces-clinical-data-presentations-at-the-2024-aacr-annual-meeting https://www.d3bio.com/press-releases/d3-bio-completes-series-a-round-to-advance-innovative-oncology-pipeline https://www.d3bio.com/press-releases/d3-bio-announces-oral-presentation-of-the-clinical-data-of-its-lead-program-d3s-001-at-the-esmo-congress-2024 https://www.d3bio.com/press-releases/d3-bio-announces-oral-presentation-of-clinical-data-for-d3s-001-at-the-2025-aacr-annual-meeting https://www.d3bio.com/press-releases/d3-bio-inc-announces-fda-breakthrough-therapy-designation-and-orphan-drug-designation-for-d3s-001-for-the-treatment-of-patients-with-kras-g12c-mutated-cancers https://www.d3bio.com/press-releases/d3-bio-showcases-breakthrough-kras-research-at-7th-ras-targeted-therapies-summit